Servatus Biopharmaceuticals Ltd's Wayne Finlayson speaks to Proactive about the first human study into Australian patients with clinically diagnosed insomnia using live biotherapeutics. The phase one and two clinical trial will run during 2022, with results expected in 2023. Close to 15% of the Australian population suffer from insomnia, with sleep disorders costing the economy and society around $51 billion annually.
Servatus Biopharmaceuticals talks Australian insomnia trial using live biotherapeutics
